Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share, and down from $2.9 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was -2.34%, with the company previously expected to post earnings of $2.3 per share but actually reporting $2.26, resulting in a surprise of -1.74% [2] - Bio-Rad's revenues for the quarter were $693.2 million, slightly surpassing the Zacks Consensus Estimate by 0.01%, and up from $667.5 million year-over-year [3] - Over the last four quarters, the company has exceeded consensus revenue estimates three times [3] Stock Performance - Bio-Rad shares have declined approximately 3.1% since the beginning of the year, while the S&P 500 has gained 1.4% [4] - The current Zacks Rank for Bio-Rad is 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.79 on revenues of $605 million, and for the current fiscal year, it is $10.36 on revenues of $2.64 billion [8] - The trend of estimate revisions for Bio-Rad was mixed ahead of the earnings release, which could change following the recent report [7] Industry Context - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Agilent Technologies, another company in the same industry, is expected to report quarterly earnings of $1.37 per share, reflecting a year-over-year increase of 4.6% [10]